Pasireotide
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cushing Disease
Conditions
Cushing Disease
Trial Timeline
Aug 13, 2004 → Jul 8, 2013
NCT ID
NCT00171951About Pasireotide
Pasireotide is a phase 2 stage product being developed by Novartis for Cushing Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00171951. Target conditions include Cushing Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03103009 | Phase 1 | Completed |
| NCT02780882 | Phase 2 | Withdrawn |
| NCT01617733 | Phase 2 | Terminated |
| NCT00698464 | Phase 1 | Completed |
| NCT00434148 | Phase 3 | Completed |
| NCT00446082 | Phase 1 | Completed |
| NCT00171730 | Phase 2 | Completed |
| NCT00171951 | Phase 2 | Completed |
Competing Products
20 competing products in Cushing Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone | AstraZeneca | Phase 2 | 52 |
| Pasireotide with or without cabergoline | Novartis | Phase 2 | 52 |
| osilodrostat + LCI699 matching placebo | Novartis | Phase 3 | 77 |
| pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg | Novartis | Phase 3 | 77 |
| LCI699 | Novartis | Phase 2 | 52 |
| Pasireotide sub-cutaneous | Novartis | Phase 3 | 77 |
| osilodrostat + osilodrostat Placebo | Novartis | Phase 3 | 77 |
| Osilodrostat | Novartis | Phase 2 | 52 |
| Pasireotide | Novartis | Phase 3 | 77 |
| Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin | Novartis | Approved | 85 |
| SOM230 s.c. | Novartis | Phase 2 | 52 |
| Lu AG13909 | Lundbeck | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| Intervention/Treatment | Recordati | Approved | 82 |
| Pasireotide | Recordati | Pre-clinical | 20 |
| LCI699 | Recordati | Phase 2 | 49 |
| Pasireotide + Cabergoline + Pasireotide LAR | Recordati | Approved | 82 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| osilodrostat | Recordati | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |